On April 20, 2020, Idorsia announced positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime performance of patients with insomnia.

Find information on this page to support you with covering the news.

Media Release

Investor webcast

An investor conference call and webcast was held on Monday April 20, 2020, to discuss the Phase 3 results with senior management.


Jean-Paul Clozel - Chief Executive Officer

Jean-Paul Clozel

Guy Braunstein - Head of Global Clinical Development

André C. Muller

Simon Jose - Chief Commercial Officer

Simon Jose

Martine Clozel - Chief Scientific Officer

Martine Clozel

More News

First quarter 2020 financial results

On April 23, 2020, Idorsia announced its financial results for the first quarter of 2020. For more information please visit the Results Day Center.